Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846128 | 1.00 | CYP2C19 (0.52) | CYP2C19ACEPPARAPPARGCYP1A2 | |
| SCHEMBL723034 | 1.00 | CYP2C19 (0.52) | CYP2C19ACEPPARAPPARGCYP1A2 | |
| SCHEMBL5418068 | 0.82 | CYP1A2 (0.55) | CYP2C19ACEPPARAPPARGCYP1A2 | |
| SCHEMBL723068 | 0.81 | CYP2C19 (0.58) | CYP2C19ACECYP1A2ALDH1A1HPGD | |
| SCHEMBL2164032 | 0.81 | METAP2 (0.50) | CYP2C19ACEPPARAPPARGMETAP2 | |
| SCHEMBL2164026 | 0.81 | METAP2 (0.50) | CYP2C19ACEPPARAPPARGMETAP2 | |
| SCHEMBL31478099 | 0.79 | CYP2C19 (0.48) | CYP2C19ACECYP1A2ALDH1A1HPGD | |
| SCHEMBL9574275 | 0.79 | CYP2C19 (0.48) | CYP2C19ACEPPARAPPARGCYP1A2 | |
| SCHEMBL11713290 | 0.79 | CYP2D6 (0.52) | CYP2C19ACECYP1A2 | |
| SCHEMBL1741031 | 0.79 | ACE (0.58) | CYP2C19ACEPPARAPPARGMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1744755-B1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2012-12-05 | — | — | EP | disclosed |
| US-8268996-B2 | Compounds and compositions as cathepsin S inhibitors | IRM LLC (BM) | 2012-09-18 | — | — | US | disclosed |
| US-20110245243-A1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | NOVARTIS AG | 2011-10-06 | — | — | US | disclosed |
| US-7985749-B2 | Compounds and compositions as cathepsin S inhibitors | NOVARTIS AG (CH) | 2011-07-26 | — | — | US | disclosed |
| US-7985749-B2 | Compounds and compositions as cathepsin S inhibitors | NOVARTIS AG (CH) | 2011-07-26 | — | — | US | disclosed |
| CN-1976710-B | Compounds and compositions as cathepsin S inhibitors | IRM LLC | 2011-03-30 | — | — | CN | disclosed |
| US-20100204200-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2010-08-12 | — | — | US | disclosed |
| US-20100204200-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2010-08-12 | — | — | US | disclosed |
| US-7732449-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2010-06-08 | — | — | US | disclosed |
| US-7732449-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2010-06-08 | — | — | US | disclosed |
| CN-1976710-A | Compounds and compositions as cathepsin S inhibitors | IRM LLC (BM) | 2007-06-06 | — | — | CN | disclosed |
| EP-1744755-A2 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM, LLC (BM) | 2007-01-24 | — | — | EP | disclosed |
| EP-1658267-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005107464-A2 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2005-11-17 | — | — | WO | disclosed |
| US-20050113356-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-05-26 | — | — | US | disclosed |
| WO-2005034848-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2005-04-21 | — | — | WO | disclosed |
| EP-0535042-B1 | ANGIOTENSIS CONVERTING ENZYME INHIBITORS | FISONS PLC (GB) | 1995-03-29 | — | — | EP | disclosed |
| US-5348978-A | Angiotensin converting enzyme inhibitors | FISONS PLC (GB) | 1994-09-20 | — | — | US | disclosed |
| EP-0535042-A1 | ANGIOTENSIS CONVERTING ENZYME INHIBITORS. | FISONS PLC (GB) | 1993-04-07 | — | — | EP | disclosed |
| WO-1992000276-A2 | ANGIOTENSIS CONVERTING ENZYME INHIBITORS | FISONS PLC (GB) | 1992-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113356-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | CYP2C19 3246/4885ACE 96/4885PPARA 3398/4885 |
| US-20110245243-A1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | CTSS, CTSB, CTSF | CYP2C19 1135/4885ACE 48/4885PPARA 1730/4885 |
| US-20100204200-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSE, CTSV | CYP2C19 350/4885ACE 463/4885PPARA 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.